{"transactions":[{"id":717667,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T21:00:26.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":1541,"price":8.6,"value":13252.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the \"ESPP\"), for the purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 2, 2026."}],"balance_after":127921,"source":{"system":"sec-edgar","filing":"0001193125-26-294863","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000119312526294863/ownership.xml","form_type":"4"}},{"id":887879,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-23T22:00:02.000Z","date":"2026-02-20","kind":"sale","planned":false,"acquired":false,"shares":4398,"price":13.62,"value":59900.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock units."}],"balance_after":126380,"source":{"system":"sec-edgar","filing":"0001193125-26-064261","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000119312526064261/ownership.xml","form_type":"4"}},{"id":893063,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-19T22:00:05.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":137500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":137500,"derivative":{"exercise_price":12.44,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":137500},"source":{"system":"sec-edgar","filing":"0001193125-26-059637","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000119312526059637/ownership.xml","form_type":"4"}},{"id":893062,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-19T22:00:05.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":68750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest on an annual basis over four years."}],"balance_after":130778,"source":{"system":"sec-edgar","filing":"0001193125-26-059637","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000119312526059637/ownership.xml","form_type":"4"}},{"id":950851,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T22:01:30.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":27,"price":6.49,"value":175.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the \"ESPP\"), for the purchase period of July 1, 2025 through December 31, 2025. This transaction is also exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,001 shares of common stock that the Reporting Person purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan for the purchase period of January 1, 2025 through June 30, 2025 that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":62028,"source":{"system":"sec-edgar","filing":"0001193125-26-002687","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000119312526002687/ownership.xml","form_type":"4"}},{"id":1252637,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-21T23:00:03.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":120000,"derivative":{"exercise_price":9.43,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000950170-25-025027","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000095017025025027/ownership.xml","form_type":"4"}},{"id":1252636,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-21T23:00:03.000Z","date":"2025-02-19","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest on an annual basis over four years."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0000950170-25-025027","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000095017025025027/ownership.xml","form_type":"4"}},{"id":1532799,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-01T01:02:10.000Z","date":"2024-04-29","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 200,000 shares of the Issuer's Common Stock, 25% of which will become vested and exercisable on April 29, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":27.12,"expiration_date":"2034-04-29","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000950170-24-050844","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000095017024050844/ownership.xml","form_type":"4"}},{"id":1833654,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-07-06T21:20:59.000Z","date":"2023-07-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":12946,"price":3.08,"value":39873.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units (\"RSUs\") were granted to the Reporting Person by the issuer under the Issuer's 2021 Stock Option and Incentive Plan on September 10, 2022. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. This transaction reflects the sufficient shares sold to pay applicable income taxes related to the 50% vesting on July 1, 2023."}],"balance_after":68054,"source":{"system":"sec-edgar","filing":"0001209191-23-041617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000120919123041617/doc4.xml","form_type":"4"}},{"id":2032674,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Appreciation Right","published_at":"2023-02-03T21:57:47.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Time Vested Stock Appreciation Right (\"TV SAR\") represents the right to receive either, (i) the largest whole number of shares of stock with a value closest to, but not in excess of, the product of the increase in fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR, multiplied by the number of shares of common stock underlying the TV SAR that is being exercised, or (ii) the Company may elect to make cash payment measured by the increase in the fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR. One-third of the TV SAR awards will vest on August 1, 2023 and the remaining two-thirds will vest on August 1, 2024. The TV SAR awards expire on February 1, 2033 and have an exercise price of $1.73 per share, the closing price of the common stock on the grant date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each Time Vested Stock Appreciation Right (\"TV SAR\") represents the right to receive either, (i) the largest whole number of shares of stock with a value closest to, but not in excess of, the product of the increase in fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR, multiplied by the number of shares of common stock underlying the TV SAR that is being exercised, or (ii) the Company may elect to make cash payment measured by the increase in the fair market value of one share of common stock from the date of grant of the TV SAR to the date of exercise of the TV SAR. One-third of the TV SAR awards will vest on August 1, 2023 and the remaining two-thirds will vest on August 1, 2024. The TV SAR awards expire on February 1, 2033 and have an exercise price of $1.73 per share, the closing price of the common stock on the grant date."}],"balance_after":150000,"derivative":{"exercise_price":1.73,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-23-006978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000120919123006978/doc4.xml","form_type":"4"}},{"id":2032673,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T21:57:47.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest as follows: one-third on August 1, 2023 and the remaining two-thirds on August 1, 2024."}],"balance_after":150000,"derivative":{"exercise_price":1.73,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-23-006978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000120919123006978/doc4.xml","form_type":"4"}},{"id":2160080,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-09-13T20:29:40.000Z","date":"2022-09-10","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent restricted stock units (\"RSUs\") issued under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":81000,"source":{"system":"sec-edgar","filing":"0000899243-22-030928","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000089924322030928/doc4.xml","form_type":"4"}},{"id":2222048,"issuer":{"id":112213,"kind":"organization","name":"Oncorus, Inc.","symbol":"ONCR"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T06:44:15.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in twelve (12) equal monthly installments commencing on July 23, 2022, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":12500,"derivative":{"exercise_price":1.6,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-22-039086","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671818/000120919122039086/doc4.xml","form_type":"4"}},{"id":2416255,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-02T23:00:57.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option shall vest as follows: 25% shall vest on February 1, 2023; and the remaining shall vest in 36 equal monthly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":9.1,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-22-004201","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000089924322004201/doc4.xml","form_type":"4"}},{"id":2416254,"issuer":{"id":15643,"kind":"organization","name":"Tourmaline Bio, Inc.","symbol":"TRML"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-02T23:00:57.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":1000,"price":13,"value":13000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired by the reporting individual under the issuer's 2021 Employee Stock Purchase Plan (\"ESPP\") in a transaction exempt under Rule 16b-3(c)."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0000899243-22-004201","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378589/000089924322004201/doc4.xml","form_type":"4"}},{"id":2663835,"issuer":{"id":112213,"kind":"organization","name":"Oncorus, Inc.","symbol":"ONCR"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T17:57:30.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in 12 equal monthly installments commencing on July 16, 2021, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":12500,"derivative":{"exercise_price":16.55,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-041617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671818/000120919121041617/doc4.xml","form_type":"4"}},{"id":4063633,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option","published_at":"2018-02-13T17:26:35.000Z","date":"2018-02-09","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter."}],"balance_after":250000,"derivative":{"exercise_price":2.9,"expiration_date":"2028-02-09","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-18-009677","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919118009677/doc4.xml","form_type":"4"}},{"id":4486919,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option","published_at":"2017-01-19T17:22:18.000Z","date":"2017-01-17","kind":"grant","acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period following the first anniversary of the grant date until the fourth anniversary of the grant date."}],"balance_after":165000,"derivative":{"exercise_price":4.11,"expiration_date":"2027-01-17","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001209191-17-004606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919117004606/doc4.xml","form_type":"4"}},{"id":4533864,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":32778,"kind":"person","name":"Fenton Mary Kay","position":1,"cik":"0001378589","reported_name":"Fenton Mary Kay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2016-12-05T17:16:38.000Z","date":"2016-12-05","kind":"purchase","acquired":true,"shares":2500,"price":4.11,"value":10275.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001209191-16-153420","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919116153420/doc4.xml","form_type":"4"}}]}